1
Spanholtz Jan: Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics.. Ipd Therapeutics, Spanholtz Jan, VAN LOON C J J, April 5, 2007: WO/2007/037682 (4 worldwide citation)

The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.


2
Spanholtz Jan: Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics. Ipd Therapeutics, Spanholtz Jan, HATZMANN MJ, October 2, 2008: WO/2008/118020 (4 worldwide citation)

The invention is related to methods for expanding and differentiating hemopoietic progenitor cells in a medium comprising a collection of cytokines, desulphated glycosaminoglycan and human serum. The invention further relates to a collection of cells obtainable by a method of the invention, use of t ...


3
Jan Spanholtz: Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells. IPD THERAPEUTICS, Hoffmann & Baron, November 24, 2015: US09193953

The invention is related to methods for expanding and differentiating hemopoietic progenitor cells in a medium comprising a collection of cytokines, desulphated glycosaminoglycan and human serum. The invention further relates to a collection of cells obtainable by a method of the invention, use of t ...


4
Jan Spanholtz: Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics. IPD THERAPEUTICS, Hoffmann & Baron, August 18, 2015: US09109202

The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.


5
Reinhard Schwartz Albiez, Michael Punzel: Method for expanding postembryonic stem and progenitor cells from umbilical cord blood and immunotherapeutic agent. IPD THERAPEUTICS, Hoffmann & Baron, June 14, 2016: US09365824

Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glyco ...


6

7
SPANHOLTZ Jan: GÉNÉRATION DE CELLULES NK ET DE PROGÉNITEURS DE CELLULES NK, GENERATION OF NK CELLS AND NK-CELL PROGENITORS. IPD THERAPEUTICS, SPANHOLTZ Jan, JANSEN C M, September 27, 2012: WO/2012/128622

The present invention provides a cytokine-based culture method for ex vivo expansion of NK cells from postembryonic hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We optimized enrichment of CD34 + cells followed by efficient expansion in gas-permeable cell cultur ...


8

9
EX VIVO NK CELL DIFFERENTIATION FROM CD34+ HEMATOPOIETIC CELLS. IPD Therapeutics, January 8, 2015: US20150010583-A1

The present invention relates to the ex vivo differentiation of NK cells from CD34+ hematopoietic stem cells. Such NK cells and their progenitor cells can be used in therapies of a broad range of malignancies. In the present invention it is shown that IL-12 modulates ex vivo NK cell differentiation. ...



Click the thumbnails below to visualize the patent trend.